Jefferies Group Reiterates “Buy” Rating for Sangamo Therapeutics (SGMO)

Sangamo Therapeutics (NASDAQ:SGMO)‘s stock had its “buy” rating reiterated by stock analysts at Jefferies Group in a report issued on Friday.

A number of other research firms have also recently commented on SGMO. BidaskClub upgraded Sangamo Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Saturday, February 17th. Wedbush reiterated a “neutral” rating and set a $6.00 target price on shares of Sangamo Therapeutics in a research report on Monday, February 12th. Zacks Investment Research cut Sangamo Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, January 5th. Piper Jaffray Companies set a $25.00 target price on Sangamo Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, January 3rd. Finally, Barclays assumed coverage on Sangamo Therapeutics in a research report on Wednesday, November 22nd. They set an “overweight” rating and a $20.00 target price on the stock. Three investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $18.83.

Sangamo Therapeutics (NASDAQ:SGMO) traded down $0.45 during trading on Friday, reaching $24.95. The company’s stock had a trading volume of 3,830,120 shares, compared to its average volume of 2,160,000. Sangamo Therapeutics has a one year low of $3.65 and a one year high of $27.50. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.64 and a current ratio of 5.64. The firm has a market capitalization of $2,110.00, a PE ratio of -35.14 and a beta of 2.87.

Sangamo Therapeutics (NASDAQ:SGMO) last posted its quarterly earnings results on Thursday, February 22nd. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.18) by $0.03. Sangamo Therapeutics had a negative return on equity of 31.81% and a negative net margin of 157.66%. The company had revenue of $13.08 million for the quarter, compared to analysts’ expectations of $11.10 million. During the same period last year, the firm earned ($0.14) earnings per share. Sangamo Therapeutics’s quarterly revenue was up 46.6% on a year-over-year basis. analysts anticipate that Sangamo Therapeutics will post -0.73 earnings per share for the current year.

In related news, VP Curt A. Herberts III sold 15,000 shares of the business’s stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $20.59, for a total value of $308,850.00. Following the transaction, the vice president now owns 29,625 shares in the company, valued at approximately $609,978.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Edward R. Conner sold 5,000 shares of the business’s stock in a transaction dated Tuesday, February 6th. The shares were sold at an average price of $18.49, for a total value of $92,450.00. The disclosure for this sale can be found here. Insiders have sold 84,953 shares of company stock worth $1,544,843 in the last quarter. Insiders own 5.50% of the company’s stock.

A number of hedge funds have recently modified their holdings of the stock. Voya Investment Management LLC increased its position in Sangamo Therapeutics by 10.7% in the 2nd quarter. Voya Investment Management LLC now owns 33,809 shares of the biopharmaceutical company’s stock valued at $298,000 after acquiring an additional 3,270 shares during the period. Raymond James Financial Services Advisors Inc. increased its position in Sangamo Therapeutics by 29.3% in the 4th quarter. Raymond James Financial Services Advisors Inc. now owns 18,962 shares of the biopharmaceutical company’s stock valued at $311,000 after acquiring an additional 4,300 shares during the period. Nationwide Fund Advisors increased its position in Sangamo Therapeutics by 13.5% in the 3rd quarter. Nationwide Fund Advisors now owns 44,892 shares of the biopharmaceutical company’s stock valued at $673,000 after acquiring an additional 5,337 shares during the period. Swiss National Bank increased its position in Sangamo Therapeutics by 3.9% in the 4th quarter. Swiss National Bank now owns 142,460 shares of the biopharmaceutical company’s stock valued at $2,336,000 after acquiring an additional 5,400 shares during the period. Finally, Rhumbline Advisers increased its position in Sangamo Therapeutics by 7.4% in the 3rd quarter. Rhumbline Advisers now owns 88,816 shares of the biopharmaceutical company’s stock valued at $1,332,000 after acquiring an additional 6,125 shares during the period. Hedge funds and other institutional investors own 68.93% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece of content was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of United States and international copyright law. The correct version of this piece of content can be read at https://www.dispatchtribunal.com/2018/02/23/jefferies-group-reiterates-buy-rating-for-sangamo-therapeutics-sgmo.html.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.

Analyst Recommendations for Sangamo Therapeutics (NASDAQ:SGMO)

Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply